We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Prenatal Test Reduces Time of Detecting Chromosomal Abnormalities

By LabMedica International staff writers
Posted on 24 Aug 2022
Print article
Image: Results from STORK prenatal genetic test, shown in foreground (Photo courtesy of Columbia University Irving Medical Center).
Image: Results from STORK prenatal genetic test, shown in foreground (Photo courtesy of Columbia University Irving Medical Center).

A newly developed prenatal test can determine if a fetus or embryo has the right number of chromosomes at a fraction of the time and cost of currently available clinical genetic tests.

Currently available prenatal genetic tests cost thousands of dollars and take days to weeks to deliver results, adding to the emotional and financial stress of fertility treatment and pregnancy and impacting treatment options.

Clinical Scientists from the Columbia University Irving Medical Center (New York, NY, USA) and their colleagues developed the new test, called STORK (Short-read Transpore Rapid Karyotyping), that can be used in the doctor's office at the point of care, delivers results in under two hours, and is about 10 times less expensive to process per sample than current tests. The nanopore-based sequencing technology was used to analyze tiny fragments of DNA 15,000 times faster than currently available chromosomal testing methods, significantly reducing the amount of time to get results. The test also uses much smaller equipment, about the size of a harmonica and weighing just 450 grams, making it accessible for use in physician offices.

The chromosomal abnormalities that this test can detect are, by far, the most common causes of miscarriage, structural anomalies, and developmental delays. Prenatal genetic testing is recommended for pregnant women who are age 35 or older, have a family history of genetic disorders, or have had one or more miscarriages. It is also used increasingly during in vitro fertilization (IVF) to test embryos prior to implantation to improve the chances of pregnancy and reduce the risk of miscarriage.

The team tested STORK in 218 blinded samples from miscarriages, pregnancies, via amniotic fluid or chorionic villi, and biopsies from embryos prior to implantation. Results were compared with those obtained using standard clinical testing. STORK results agreed with standard clinical testing in all of the pregnancy-related samples and in 98% of the embryos tested. For miscarriage samples, STORK was more accurate than standard testing and was determined to have correctly identified chromosome numbers in the 10 cases for which the two tests disagreed. An additional 60 pregnancy samples were tested with STORK at an independent certified laboratory, and those results were identical to results obtained with standard clinical testing.

Zev Williams, MD, PhD, Associate Professor of Women's Health and a senior author of the study, said, “The affordability of this test also means that individuals who have suffered a miscarriage do not have to wait until a second or third loss before insurance will cover expensive lab tests, leaving many women in the dark and often blaming themselves. Our study also shows that our rapid test was better than the gold standard for testing miscarriage samples, giving women who have suffered a pregnancy loss a sense of closure and the ability to take steps to prevent another loss.” The study was published on August 18, 2022 in the New England Journal of Medicine.

HLX
Gold Supplier
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
New
HLA-B27 Real Time PCR Test
RIDA GENE HLA-B27
New
Diagnostic Salivary DHEA ELISA Kit
Salimetrics Salivary DHEA Enzyme Immunoassay Kit

Print article

Channels

Molecular Diagnostics

view channel
Image: The Geo portable testing platform integrated with the Snap collection device (Photo courtesy of ReadyGo Diagnostics)

Ultra-Portable Rapid Test Platform Offers Complete Sample-to-Answer Solution for Remote and Off-Grid Testing

An ultra-portable isothermal molecular diagnostics system integrated with a patented device which combines sample collection and processing into a single, easy-to-use disposable is set to revolutionize... Read more

Hematology

view channel
Image: The Atellica HEMA 570 and 580 hematology analyzers remove workflow barriers (Photo courtesy of Siemens)

Next-Gen Hematology Analyzers Eliminate Workflow Roadblocks and Achieve Fast Throughput

Hematology testing is a critical aspect of patient care, utilized to establish a patient's health baseline, track treatment progress, or guide timely modifications to care. However, increasing constraints... Read more

Immunology

view channel
Image: Newly observed anti-FSP antibodies have also been found to predict immune-related adverse events (Photo courtesy of Calviri)

First Blood-Based Biomarkers Test to Predict Treatment Response in Cancer Patients

Every year worldwide, lung cancer afflicts over two million individuals and almost the same number of people succumb to the disease. This malignancy leads the charts in cancer-related mortalities, with... Read more

Microbiology

view channel
Image: The rapid MTB strip test for tuberculosis can identify TB patients within two hours (Photo courtesy of Chulalongkorn University)

Rapid MTB Strip Test Detects Tuberculosis in Less Than an Hour without Special Tools

Tuberculosis (TB), a highly infectious disease, continues to pose significant challenges to public health worldwide. TB is caused by a bacterium known as "Mycobacterium tuberculosis," spreading through... Read more

Pathology

view channel
Image: The UNIQO 160 (CE-IVDR) advances diagnostic analysis for autoimmune diseases (Photo courtesy of EUROIMMUN)

Novel Automated IIFT System Enables Cutting-Edge Diagnostic Analysis

A newly-launched automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics offers an all-in-one solution to enhance the efficiency of the complete IIFT process, comprising... Read more

Technology

view channel
Electronic biosensor uses DNA aptamers for detecting biomarkers in whole blood samples (Photo courtesy of Freepik)

Electronic Biosensor Detects Biomarkers in Whole Blood Samples without Addition of Reagents

The absence of robust, reliable, and user-friendly bioanalytical tools for early and timely diagnosis of cardiovascular diseases, particularly sudden cardiac arrest, leads to preventable deaths and imposes... Read more

Industry

view channel
Image: The global HbA1c testing devices market is expected to reach USD 2.56 billion in 2027 (Photo courtesy of Freepik)

Global Hemoglobin A1c Testing Devices Market Driven by Rising Prevalence of Diabetes

Hemoglobin A1c (HbA1c), or glycated hemoglobin, refers to hemoglobin with glucose attached. HbA1c testing devices are used for blood tests that determine average blood glucose, or blood sugar levels.... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.